Although many reported preclinical studies using albumin-binding PSMA-based 177Lu-labeled therapeutics were conducted using the PSMA+ PC3 PIP tumor model, these studies mainly used athymic nude mice for tumor implantation. This evidence concerns the gene FOLH1 and neoplasm.